FDA and FTC warn public of fraudulent 2009 H1N1 (swine) influenza products

The FDA and FTC are alerting the public to be wary of internet sites and other promotions for products that claim to diagnose, prevent, mitigate, treat, or cure the 2009 H1N1 influenza virus, commonly known as swine flu. Many of these products, including dietary supplements or other food products, products purporting to be drugs, devices, or vaccines are being sold over the Internet via illegitimate web sites. Such fraudulent products will not prevent the transmission of the virus or offer effective treatment against H1N1 influenza virus infection. The agencies are advising operators of the offending websites to promptly correct and/or remove promotions of these fraudulent products or face enforcement action.

The two FDA-approved antiviral drugs for treatment and prophylaxis of the 2009 H1N1 influenza virus are Tamiflu (oseltamivir, from Roche) and Relenza (zanamivir, from GlaxoSmithKline).  Tamiflu and Relenza, in addition to their approved labeling, have Emergency Use Authorizations (EUAs) that describe specific authorized uses during this public health emergency. Consumers should contact their healthcare professional or legitimate medical supply services with questions or concerns about medical products or personal protective equipment.

For more information visit www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149576.htm.